Imipramine Tapering Guide For Safe Withdrawal

Imipramine should generally be reduced gradually rather than stopped abruptly, under the guidance of a healthcare professional. There is no single tapering schedule that will be appropriate for everyone. Recommendations vary considerably depending on the source, while factors such as how long imipramine has been taken, the current dose, previous withdrawal experiences and the person's response to dose reductions can all influence how gradually a taper may need to proceed.

Several sources provide guidance on reducing imipramine and other antidepressants, ranging from the Canadian product monograph's general recommendation to taper over several weeks to the much more gradual, hyperbolic approaches described in the Maudsley Deprescribing Guidelines. The table below compares these approaches before we look at each one in more detail.

Imipramine Tapering Approaches at a Glance

Why are these Imipramine recommendations so different?

There is no single universally accepted tapering schedule for imipramine. The Canadian product monograph provides relatively broad advice to taper over several weeks, while MedStopper offers a practical staged example that can be slowed if needed. National Institute for Health and Care Excellence (NICE) and the Royal College of Psychiatrists (RCPsych) emphasize progressively smaller, symptom-guided reductions.

The Maudsley Deprescribing Guidelines go considerably further by providing imipramine-specific hyperbolic tapering examples based on estimated changes in serotonin transporter occupancy.

These approaches should therefore be understood as different frameworks for planning a taper rather than competing prescriptions for one correct schedule.

What Do the Maudsley Deprescribing Guidelines Suggest for Imipramine?

The Maudsley Deprescribing Guidelines provide detailed guidance for tapering imipramine. Rather than recommending a single tapering schedule, the guidelines present several example approaches based on the relationship between dose and serotonin transporter (SERT) receptor occupancy.

The authors explain that the relationship between imipramine dose and its effects at serotonin transporters is hyperbolic rather than linear. This means that reducing by the same number of milligrams at each step can produce increasingly large changes in receptor occupancy as the dose becomes lower. For example, a sequence such as 100 mg → 75 mg → 50 mg → 25 mg → 0 mg involves progressively larger changes in effect despite each reduction being 25 mg.

To produce more consistent changes in receptor occupancy, the Maudsley Deprescribing Guidelines instead provide tapering examples in which the reductions become progressively smaller as the dose decreases.

Three example approaches are presented:

• A faster taper, with up to an 11-percentage-point change in SERT occupancy between steps, taking approximately 5–10 months.
• A moderate taper, with up to a 5.5-percentage-point change between steps, taking approximately 10–20 months.
• A slower taper, with approximately a 2.8-percentage-point change between steps, taking approximately 20–40 months.

In these examples, reductions are generally spaced about 2–4 weeks apart. However, the guidelines emphasize that these schedules are examples rather than prescriptive regimens.

The pace can be modified according to the person's circumstances and response to each reduction. Some people may tolerate a faster taper, particularly after relatively short-term use, while others may require smaller reductions and a considerably longer taper.

The guidelines recommend making subsequent reductions once withdrawal symptoms from the previous reduction have largely resolved, helping to avoid an accumulation of withdrawal symptoms. If symptoms are more difficult or take longer to resolve, further reductions can be postponed and the taper made more gradual. The authors also note that some people may need reductions smaller than those shown in their slowest example, including additional intermediate doses or a microtapering approach.

What Does the Canadian Product Monograph Say About Tapering Imipramine?

The Canadian product monograph for imipramine recommends gradually tapering the dose over several weeks when discontinuing treatment, rather than stopping the medication abruptly. It also recommends close monitoring during discontinuation. The monograph does not, however, provide a specific tapering schedule, percentage reduction or dose-by-dose protocol.

The monograph recognizes that withdrawal symptoms can occur following abrupt discontinuation. After prolonged treatment, reported symptoms include nausea, headache and malaise. Rare cases of mania or hypomania have also been reported within 2–7 days after stopping chronic tricyclic antidepressant therapy.

In Canada, this imipramine product is available as 10 mg, 25 mg, 50 mg and 75 mg tablets. The 75 mg tablet is described as scored, while the lower-strength tablets are not described as scored. The monograph instructs that imipramine tablets should be swallowed whole with water. These available dosage forms become an important practical consideration when planning progressively smaller dose reductions.

What about U.S. prescribing information?

U.S. prescribing information also recognizes withdrawal symptoms following abrupt discontinuation of prolonged imipramine treatment, including nausea, headache and malaise. Current U.S. labeling is available for 10 mg, 25 mg and 50 mg tablets.

What Does MedStopper Suggest for Tapering Imipramine?

MedStopper suggests that for people who have taken imipramine daily for more than 3–4 weeks, one approach is to reduce the dose by 25% each week—to 75%, 50%, and then 25% of the original dose. The taper can be extended if needed, including using smaller reductions of around 10%.

If withdrawal symptoms become intolerable, MedStopper suggests returning to the previously tolerated dose until symptoms resolve and then planning a more gradual taper.

It also notes that reductions may need to become smaller at lower doses and emphasizes that the person taking the medication should ultimately guide the pace of discontinuation.

MedStopper lists possible withdrawal symptoms including nausea, diarrhea, sweating, headache, dizziness, flu-like symptoms, fatigue, anxiety, restlessness, insomnia, vivid dreams, tremor, muscle aches, confusion, palpitations, unusual movements and mood changes.

Important: This is one suggested tapering approach rather than a personalized schedule. The appropriate pace can vary considerably depending on how long imipramine has been taken, the current dose, previous withdrawal experiences and how the person responds to each reduction.

What Do Other Clinical Guidelines Recommend?

Royal College of Psychiatrists

The Royal College of Psychiatrists recommends gradually reducing antidepressants rather than stopping them suddenly. For people who have taken an antidepressant for many months or years, experienced withdrawal during previous attempts, or are taking a medication associated with greater withdrawal risk, it recommends considering smaller reductions and a longer taper.

Dose reductions generally become smaller as the dose decreases, and some people may need to reach a very low dose before stopping completely.

The RCPsych provides example approaches ranging from reductions of approximately 50% every 2–4 weeks for some people to much more gradual reductions of approximately 10% or 5% when a slower taper is needed. These are presented as starting points rather than fixed schedules, with the taper adjusted according to the person's response and withdrawal symptoms.

Although the RCPsych does not provide an imipramine-specific example taper, its guidance is relevant because imipramine is a tricyclic antidepressant.

NICE Guidelines

NICE similarly recommends reducing antidepressants in stages when stopping treatment. Its current guidance supports reductions that become progressively smaller as the dose decreases and emphasizes that the pace should be guided by the person's response, with further reductions delayed until withdrawal symptoms have resolved or become tolerable.

This is consistent with the Canadian imipramine product monograph's recommendation to taper gradually, but NICE and the RCPsych provide more detail about individualizing the size and timing of reductions, particularly for people who have difficulty with withdrawal.

Comparing the Different Imipramine Tapering Approaches

Although these approaches differ considerably in pace and structure, several common themes emerge. All support gradual dose reduction rather than abruptly stopping imipramine, while the more detailed guidance emphasizes adjusting the taper according to the person's response.

The major difference is how reductions are structured. The Canadian product monograph provides broad advice to taper over several weeks, MedStopper offers a staged approach that can be slowed when needed, and NICE and the Royal College of Psychiatrists emphasize progressively smaller, symptom-guided reductions.

The Maudsley Deprescribing Guidelines go further by providing imipramine-specific examples based on estimated changes in serotonin transporter occupancy.

Taken together, these sources support approaching an imipramine taper as an individualized process rather than a fixed schedule.

What Could a Hyperbolic Taper of Imipramine Look Like?

A hyperbolic taper does not mean reducing imipramine by the same number of milligrams at every step. Instead, the reductions generally become progressively smaller as the dose decreases, with the aim of producing smaller and more consistent changes in the medication's pharmacological effects.

The Maudsley Deprescribing Guidelines provide several imipramine-specific examples based on estimated changes in serotonin transporter (SERT) occupancy. Their faster example illustrates what this can look like in practice:

Imipramine Tapering Calculator

The Maudsley example above illustrates one approach to constructing progressively smaller dose reductions. The calculator below provides another way to explore this general principle by applying a percentage reduction to the previous dose at each step. It uses a proportional percentage-based calculation rather than estimating serotonin transporter occupancy, so it should not be interpreted as reproducing the Maudsley schedules.

The calculator then generates an example schedule in which each reduction is calculated from the previous dose rather than the original starting dose. This causes the reductions to become progressively smaller as the dose decreases.

You can change the settings and regenerate the schedule to see how different reduction percentages or intervals affect the overall taper. The results are intended as an educational planning tool rather than individualized medical advice, and the doses calculated may not always correspond to commercially available or practically measurable imipramine doses.

How Does Imipramine Work, and Why Might This Matter During Tapering?

Imipramine is a tricyclic antidepressant that affects several neurotransmitter systems. Its primary antidepressant action involves inhibiting the reuptake of serotonin and norepinephrine, but it also blocks muscarinic acetylcholine, histamine H1 and alpha-adrenergic receptors. These additional receptor effects contribute to imipramine's broader pharmacological profile and many of its characteristic side effects.

One reason this may matter during tapering is imipramine's anticholinergic activity. Muscarinic receptors normally respond to acetylcholine and are involved in functions such as gastrointestinal activity, glandular secretions and heart rate. Imipramine suppresses some of these cholinergic effects by blocking muscarinic receptors.

After ongoing exposure to an anticholinergic medication such as imipramine, the nervous system may adapt to its effects. When a tricyclic antidepressant is reduced or stopped, increased cholinergic activity has been proposed as one mechanism behind some withdrawal symptoms—a phenomenon commonly described as cholinergic rebound.

This may contribute particularly to gastrointestinal and physical symptoms such as nausea, abdominal discomfort, diarrhea and sweating. Other withdrawal symptoms may arise through different mechanisms, so not every symptom experienced during an imipramine taper should be attributed to cholinergic rebound.

Why Smaller Imipramine Reductions May Matter at Lower Doses

The relationship between imipramine dose and its effects at serotonin transporters is not linear. According to the Maudsley Deprescribing Guidelines, progressively smaller doses can continue to produce meaningful changes in estimated serotonin transporter (SERT) occupancy. This means that reducing by the same number of milligrams throughout a taper can result in increasingly large changes in pharmacological effect as the dose gets lower.

This is the rationale behind the hyperbolic tapering examples described earlier. Rather than using equal milligram reductions all the way to zero, the reductions become progressively smaller toward the end of the taper. The Maudsley authors note that some people may require even smaller intermediate reductions than those shown in their example schedules, particularly if withdrawal symptoms become difficult to tolerate.

How to Get Smaller Imipramine Doses

One practical challenge with a gradual imipramine taper is that the calculated doses may eventually become smaller than those readily available as standard tablets. In Canada, imipramine hydrochloride is available in 10 mg, 25 mg, 50 mg and 75 mg tablets, and there is no commercially available liquid formulation listed in the Maudsley Deprescribing Guidelines for Canada.

The guidelines discuss several ways smaller doses may sometimes be produced, including appropriately divided tablets, compounded preparations and, where available, liquid formulations. They also discuss preparing an immediate-use liquid from crushed imipramine hydrochloride tablets, while noting limitations around stability. These methods require appropriate professional guidance because the suitability of splitting, crushing or compounding can depend on the specific product and formulation.

The Maudsley guidelines also specifically advise against using every-other-day dosing as a way of obtaining a lower average dose of imipramine. With an imipramine half-life of approximately 19 hours, skipping days can produce substantial fluctuations in drug concentrations rather than the more consistent exposure achieved through smaller daily doses.

What Can Affect an Imipramine Taper?

There is no single pace of tapering that will suit everyone taking imipramine. How someone responds to dose reductions can vary, and a taper may need to be adjusted along the way rather than following a predetermined schedule from beginning to end.

Factors that may influence how an imipramine taper is approached include:

• How long imipramine has been taken. Longer-term use may require a more gradual approach, while people who have taken an antidepressant for a relatively short period may sometimes be able to reduce more quickly.
• The current dose. As discussed above, the relationship between dose and pharmacological effect is not linear. Smaller reductions may therefore become increasingly important toward the lower end of a taper.
• Previous withdrawal experiences. Someone who has previously experienced difficult withdrawal after reducing or stopping an antidepressant may choose a more cautious approach.
• Response to each reduction. Withdrawal symptoms can provide useful information about whether the current pace is tolerable. Several guidelines recommend allowing symptoms to resolve or become manageable before making another reduction.
• Available formulations. The ability to make progressively smaller reductions can depend on the tablet strengths, liquid preparations or compounded doses that are practically available.
• Other medications and health considerations. Other prescribed medications, changes to medications, medical conditions and individual circumstances can complicate the interpretation of symptoms during a taper.
• Life circumstances and support. Stress, sleep disruption, major life changes and the availability of practical or emotional support may also affect how manageable the tapering process feels.

A tapering plan therefore does not necessarily need to remain unchanged once it has begun. Holding at a dose for longer, making a smaller next reduction or otherwise adjusting the pace in response to symptoms and circumstances can all be part of an individualized tapering process.

Imipramine Withdrawal Symptoms

Imipramine withdrawal can involve a range of physical, neurological, sleep-related and psychological symptoms. MedStopper lists several possible symptoms when reducing or stopping imipramine, while the Maudsley Deprescribing Guidelines also discuss withdrawal from tricyclic antidepressants in the context of cholinergic rebound. Possible symptoms include:

Frequently Asked Questions About Imipramine Tapering

Can you stop imipramine suddenly?

Imipramine generally should not be stopped suddenly after ongoing treatment. The Canadian product monograph recommends gradually tapering the dose over several weeks and monitoring during discontinuation. Abrupt cessation after prolonged treatment may produce symptoms including nausea, headache and malaise.

How do you taper off imipramine?

There is no single imipramine tapering schedule that is appropriate for everyone. Guidance ranges from relatively brief gradual reductions to much slower approaches involving progressively smaller dose reductions. Factors such as duration of treatment, current dose, previous withdrawal experiences and response to each reduction can influence the pace of a taper.

How long does it take to taper off imipramine?

The length of an imipramine taper can vary considerably. As discussed earlier, the Canadian product monograph broadly describes tapering over several weeks, while the Maudsley Deprescribing Guidelines provide examples ranging from approximately 5–10 months to 20–40 months, with the possibility of even slower reductions for some people. These are examples rather than timelines everyone should follow.

What are the symptoms of imipramine withdrawal?

Possible withdrawal symptoms include nausea, abdominal cramping, diarrhea, sweating, headache, dizziness, fatigue, anxiety, restlessness, sleep disturbance, vivid dreams, tremor, muscle aches, confusion, palpitations and mood changes. The Canadian product information specifically identifies withdrawal symptoms following sudden discontinuation, while historical reports of imipramine withdrawal have also documented gastrointestinal, neurological and anxiety symptoms.

How long do imipramine withdrawal symptoms last?

There isn't a reliable duration that applies to everyone. Withdrawal can vary depending on factors such as how long imipramine has been taken, the dose, how quickly it is reduced and individual response. This is one reason guidelines increasingly emphasize adjusting subsequent reductions according to how the person responds rather than following a rigid timetable.

Why might imipramine reductions need to get smaller at lower doses?

The relationship between imipramine dose and serotonin transporter occupancy is nonlinear. This means that the same milligram reduction can have a different pharmacological effect depending on where it occurs in the dose range. Hyperbolic tapering approaches therefore use progressively smaller reductions as the dose decreases.

Can I take imipramine every other day while tapering?

The Maudsley Deprescribing Guidelines advise against every-other-day dosing for imipramine. RCPsych also generally advises against skipping antidepressant doses on some days because this can cause fluctuations in drug levels and increase the likelihood of withdrawal symptoms.

References

AA Pharma Inc. (2024). Imipramine hydrochloride tablets: Product monograph. Health Canada.

Horowitz, M. A., & Taylor, D. M. (2024). The Maudsley deprescribing guidelines: Antidepressants, benzodiazepines, gabapentinoids and Z-drugs. John Wiley & Sons.

MedStopper. (n.d.). MedStopper: A deprescribing resource for healthcare professionals and their patients. University of British Columbia.

National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NICE guideline NG222).

Royal College of Psychiatrists. (n.d.). Stopping antidepressants.

U.S. National Library of Medicine. (2026). Imipramine hydrochloride tablet [Drug label]. DailyMed.